

SinoMab appoints new President for China operations

07 November 2022 | News

With rich experience and practical achievements in corporate strategic management

SinoMab BioScience, a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, has announced that Shanchun Wang has been appointed as the President (China) of the company. Wang will mainly be responsible for the China operation.

Wang served as the executive director of Sino Biopharmaceutical and the president of Chia Tai - Tianqing Pharmaceutical Group Co., joined SinoMab lately as the President (China) of the company.

He has rich experience and practical achievements in corporate strategic management, organisational management, innovation research and development and product commercialization. He is a specialist that granted the special government allowances of the State Council and awarded as a national model worker, a Jiangsu Province Technology Advanced Worker, a Jiangsu Province Model Labour, a winner of the Shanghai Technology Advancement First Honour Award, a Jiangsu Province Outstanding Entrepreneur, a Jiangsu Province Young and Middle-aged Expert with Outstanding Contribution, a Jiangsu Advanced Individual with Outstanding Contribution in Manufacture etc.